LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
A live audio webcast will be available under the "Events and Presentations" section of LogicBio's website, found here: https://investor.logicbio.com/events-and-presentations/events. A replay of the webcast will become available within 24 hours following the presentation and will be archived for 30 days.
LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with low levels of pre-existing neutralizing antibodies in human samples and with improved manufacturability. Top-tier capsid candidates from this effort have demonstrated significant improvements over benchmark AAVs currently in clinical development. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations.
This press release contains "forward-looking" statements within the meaning of the federal securities laws, including with respect to the Company's management transition, upcoming development milestones and the timing of patient enrollment in the phase 1/2 SUNRISE clinical trial. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company's current and future research and development activities and preclinical studies and potential future clinical trials. These risks are discussed in the Company's filings with the